利干德制药

最新新闻

• 评级变动
  RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $345
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $388
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $388 to $397
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $266
  \u5e02\u573a\u8d44\u8baf · 2026/5/28
• Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $397
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $335
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $326
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $266
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• Barclays Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $345
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $358
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $332
  \u5e02\u573a\u8d44\u8baf · 2026/7/8
• 评级变动
  Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $387
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $358
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $332
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $340
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390
  \u5e02\u573a\u8d44\u8baf · 2026/8/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。